Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2020

01-05-2020 | Acute Myeloid Leukemia | Case Report

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature

Authors: Giacomo Coltro, Francesco Mannelli, Federica Vergoni, Raffaella Santi, Daniela Massi, Luisa Margherita Siliani, Antonella Marzullo, Stefania Bonifacio, Elisabetta Pelo, Annalisa Pacilli, Chiara Paoli, Annalisa Franci, Laura Calabresi, Alberto Bosi, Alessandro Maria Vannucchi, Paola Guglielmelli

Published in: Clinical and Experimental Medicine | Issue 2/2020

Login to get access

Abstract

Splenomegaly is a key clinical manifestation of myelofibrosis, and splenectomy is currently indicated in patients with drug refractory, symptomatic splenomegaly or with the aim of improving refractory cytopenias. Transformation to acute myeloid leukemia occurs in up to 20% of patients with myelofibrosis, while cases of myeloid sarcoma have been reported very unfrequently. In this manuscript, we report the case of a 60-year-old man with a history of primary myelofibrosis who underwent splenectomy because of drug-refractory massive splenomegaly, systemic symptoms and anemia. At the opening of the peritoneal cavity, the spleen resulted massively enlarged and tenaciously entrapped by a pervasive neoplastic-like tissue. The extensive involvement of the abdomen fatally complicated the surgical procedure. At postmortem examination, the spleen showed a diffuse infiltration of immature cells that were also found in the peritoneum, bowel, liver, lungs and myocardium. After immunohistochemical, cytogenetic, flow cytometric and molecular characterization of neoplastic population, a diagnosis of disseminated myeloid sarcoma of the spleen was made. This case report highlights a very unusual case of myeloid sarcoma originating from the spleen in a patient with myelofibrosis who had no evidence of bone marrow or peripheral blood involvement by leukemic cells. Molecular characterization showed that leukemic cells originated from the founding clone of the chronic phase. The sarcoma could not be suspected based on clinical findings and was diagnosed only at the time of surgical procedure and autopsy. This case suggests that leukemic transformation of myelofibrosis can originate outside the bone marrow and, presumably rarely, present as a granulocytic sarcoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;1:1057–69.CrossRef Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;1:1057–69.CrossRef
2.
go back to reference Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95(7):2226–33.CrossRef Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95(7):2226–33.CrossRef
3.
go back to reference Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361–70.CrossRef Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361–70.CrossRef
4.
go back to reference Tefferi A, Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, et al. Risk factors and a prognostic model for post-splenectomy survival in myelofibrosis. Am J Hematol. 2017;92:1187–92.CrossRef Tefferi A, Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, et al. Risk factors and a prognostic model for post-splenectomy survival in myelofibrosis. Am J Hematol. 2017;92:1187–92.CrossRef
5.
go back to reference Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13.CrossRef Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13.CrossRef
6.
go back to reference Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2010;29(4):392–7.CrossRef Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2010;29(4):392–7.CrossRef
7.
go back to reference Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013;13(3):315–8.CrossRef Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013;13(3):315–8.CrossRef
8.
go back to reference Tefferi A, Lasho T, Finke C, Knudson R, Ketterling R, Hanson C, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–7.CrossRef Tefferi A, Lasho T, Finke C, Knudson R, Ketterling R, Hanson C, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–7.CrossRef
9.
go back to reference Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861.CrossRef Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861.CrossRef
10.
go back to reference Tefferi A, Guglielmelli P, Lasho T, Rotunno G, Finke C, Mannarelli C, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–500.CrossRef Tefferi A, Guglielmelli P, Lasho T, Rotunno G, Finke C, Mannarelli C, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–500.CrossRef
11.
go back to reference Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef
12.
go back to reference Polliack A, Prokocimer M, Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol. 1980;9(2):211–20.CrossRef Polliack A, Prokocimer M, Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol. 1980;9(2):211–20.CrossRef
13.
go back to reference Dunphy CH, Kitchen S, Saravia O, Velasquez WS. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Am J Hematol. 1996;51(1):85–9.CrossRef Dunphy CH, Kitchen S, Saravia O, Velasquez WS. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Am J Hematol. 1996;51(1):85–9.CrossRef
14.
go back to reference Morita K, Nakamine H, Inoue R, Takano M, Takeda M, Enomoto Y, et al. Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression. Pathol Int. 2012;62(6):433–7.CrossRef Morita K, Nakamine H, Inoue R, Takano M, Takeda M, Enomoto Y, et al. Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression. Pathol Int. 2012;62(6):433–7.CrossRef
15.
go back to reference Barnes HM, Prchal JT, Scott C. Extramedullary blast transformation in the central nervous system in idiopathic myelofibrosis. Am J Hematol. 1981;11(3):305–8.CrossRef Barnes HM, Prchal JT, Scott C. Extramedullary blast transformation in the central nervous system in idiopathic myelofibrosis. Am J Hematol. 1981;11(3):305–8.CrossRef
16.
go back to reference Kim M, Huh J. Primary myelofibrosis and extramedullary blastic transformation with hemophagocytosis. Korean J Hematol. 2012;47(4):244.CrossRef Kim M, Huh J. Primary myelofibrosis and extramedullary blastic transformation with hemophagocytosis. Korean J Hematol. 2012;47(4):244.CrossRef
17.
go back to reference Fukushima T, Uchida M, Iwasaki H, Kamiya K, Tanaka T, Yoshimura T, et al. Blastic crisis of primary myelofibrosis associated with multiple myeloblastomas. [Rinsho ketsueki] Jpn J Clin Hematol. 1990;31(1):95–9. Fukushima T, Uchida M, Iwasaki H, Kamiya K, Tanaka T, Yoshimura T, et al. Blastic crisis of primary myelofibrosis associated with multiple myeloblastomas. [Rinsho ketsueki] Jpn J Clin Hematol. 1990;31(1):95–9.
18.
19.
go back to reference Pileri S, Ascani S, Cox M, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340.CrossRef Pileri S, Ascani S, Cox M, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340.CrossRef
20.
go back to reference Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016;40(11):1473–83.CrossRef Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016;40(11):1473–83.CrossRef
21.
go back to reference Jaffe ES. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001. Jaffe ES. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
22.
go back to reference Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426–37.CrossRef Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426–37.CrossRef
23.
go back to reference Lan T-Y, Lin D-T, Tien H-F, Yang R-S, Chen C-Y, Wu K. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol. 2009;122(4):238–46.CrossRef Lan T-Y, Lin D-T, Tien H-F, Yang R-S, Chen C-Y, Wu K. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol. 2009;122(4):238–46.CrossRef
24.
go back to reference Porcu P, Neiman RS, Orazi A, Barosi G, Guarnone R, Thielc J, et al. Splenectomy in myelofibrosis with myeloid metaplasia (MMM): a single institution experience with 223 patients. Blood J Am Soc Hematol. 1999;93(6):2132–4. Porcu P, Neiman RS, Orazi A, Barosi G, Guarnone R, Thielc J, et al. Splenectomy in myelofibrosis with myeloid metaplasia (MMM): a single institution experience with 223 patients. Blood J Am Soc Hematol. 1999;93(6):2132–4.
25.
go back to reference Miwa Y, Hayashi T, Suzuki S, Abe S, Onishi I, Kirimura S, et al. Up-regulated expression of CXCL12 in human spleens with extramedullary haematopoiesis. Pathology. 2013;45(4):408–16.CrossRef Miwa Y, Hayashi T, Suzuki S, Abe S, Onishi I, Kirimura S, et al. Up-regulated expression of CXCL12 in human spleens with extramedullary haematopoiesis. Pathology. 2013;45(4):408–16.CrossRef
26.
go back to reference Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, Orazi A. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol. 2012;25(6):815–27.CrossRef Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, Orazi A. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol. 2012;25(6):815–27.CrossRef
27.
go back to reference Wang X, Prakash S, Lu M, Tripodi J, Ye F, Najfeld V, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Investig. 2012;122(11):3888–99.CrossRef Wang X, Prakash S, Lu M, Tripodi J, Ye F, Najfeld V, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Investig. 2012;122(11):3888–99.CrossRef
28.
go back to reference Bacher U, Asenova S, Badbaran A, Zander AR, Alchalby H, Fehse B, et al. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med. 2010;10(3):205–8.CrossRef Bacher U, Asenova S, Badbaran A, Zander AR, Alchalby H, Fehse B, et al. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med. 2010;10(3):205–8.CrossRef
29.
go back to reference Jacobs P, Sellars S. Granulocytic sarcoma preceding leukaemic transformation in myelofibrosis. Postgrad Med J. 1985;61(722):1069.CrossRef Jacobs P, Sellars S. Granulocytic sarcoma preceding leukaemic transformation in myelofibrosis. Postgrad Med J. 1985;61(722):1069.CrossRef
30.
go back to reference Chan AC, Kwong Y-L, Lam CC. Granulocytic sarcoma of megakaryoblastic differentiation complicating chronic idiopathic myelofibrosis. Hum Pathol. 1996;27(4):417–20.CrossRef Chan AC, Kwong Y-L, Lam CC. Granulocytic sarcoma of megakaryoblastic differentiation complicating chronic idiopathic myelofibrosis. Hum Pathol. 1996;27(4):417–20.CrossRef
31.
go back to reference Kasahara S, Tsurumi H, Hara T, Goto H, Moriwaki H. Idiopathic myelofibrosis developing isolated granulocytic sarcoma with der (1; 7)(q10; p10) after splenectomy and finally transforming to acute myelogenous leukemia. Leuk Lymphoma. 2000;39(3–4):427–33.CrossRef Kasahara S, Tsurumi H, Hara T, Goto H, Moriwaki H. Idiopathic myelofibrosis developing isolated granulocytic sarcoma with der (1; 7)(q10; p10) after splenectomy and finally transforming to acute myelogenous leukemia. Leuk Lymphoma. 2000;39(3–4):427–33.CrossRef
32.
go back to reference Hirose Y, Masaki Y, Shimoyama K, Sugai S, Nojima T. Granulocytic sarcoma of megakaryoblastic differentiation in the lymph nodes terminating as acute megakaryoblastic leukemia in a case of chronic idiopathic myelofibrosis persisting for 16 years. Eur J Haematol. 2001;67(3):194–8.CrossRef Hirose Y, Masaki Y, Shimoyama K, Sugai S, Nojima T. Granulocytic sarcoma of megakaryoblastic differentiation in the lymph nodes terminating as acute megakaryoblastic leukemia in a case of chronic idiopathic myelofibrosis persisting for 16 years. Eur J Haematol. 2001;67(3):194–8.CrossRef
33.
go back to reference Lu Y, Huang Q. Primary myelofibrosis relapsed with duodenal myeloid sarcoma after allogeneic stem cell transplantation. Leuk Lymphoma. 2009;50(11):1879–81.CrossRef Lu Y, Huang Q. Primary myelofibrosis relapsed with duodenal myeloid sarcoma after allogeneic stem cell transplantation. Leuk Lymphoma. 2009;50(11):1879–81.CrossRef
34.
go back to reference Yoshiki Y, Asai T, Ichikawa M, Hangaishi A, Ota S, Imai Y, et al. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia. Intern Med. 2011;50(21):2649–52.CrossRef Yoshiki Y, Asai T, Ichikawa M, Hangaishi A, Ota S, Imai Y, et al. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia. Intern Med. 2011;50(21):2649–52.CrossRef
35.
go back to reference Orofino N, Cattaneo D, Bucelli C, Pettine L, Fabris S, Gianelli U, et al. An unusual type of myeloid sarcoma localization following myelofibrosis: a case report and literature review. Leuk Res Rep. 2017;8:7–10.PubMedPubMedCentral Orofino N, Cattaneo D, Bucelli C, Pettine L, Fabris S, Gianelli U, et al. An unusual type of myeloid sarcoma localization following myelofibrosis: a case report and literature review. Leuk Res Rep. 2017;8:7–10.PubMedPubMedCentral
36.
go back to reference C̆olović M, Vidović A, Janković M, C̆olović N, Jovanović MPI. Myeloid sarcoma of the testis and skin with osteolytic bone lesions in blastic transformation of primary myelofibrosis. Lab Med. 2013;44(3):258–61.CrossRef C̆olović M, Vidović A, Janković M, C̆olović N, Jovanović MPI. Myeloid sarcoma of the testis and skin with osteolytic bone lesions in blastic transformation of primary myelofibrosis. Lab Med. 2013;44(3):258–61.CrossRef
37.
go back to reference Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 1981;48(6):1426–37.CrossRef Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 1981;48(6):1426–37.CrossRef
Metadata
Title
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature
Authors
Giacomo Coltro
Francesco Mannelli
Federica Vergoni
Raffaella Santi
Daniela Massi
Luisa Margherita Siliani
Antonella Marzullo
Stefania Bonifacio
Elisabetta Pelo
Annalisa Pacilli
Chiara Paoli
Annalisa Franci
Laura Calabresi
Alberto Bosi
Alessandro Maria Vannucchi
Paola Guglielmelli
Publication date
01-05-2020
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-020-00616-5

Other articles of this Issue 2/2020

Clinical and Experimental Medicine 2/2020 Go to the issue